T-FITNESS: Toward empowering CAR-T therapies for solid tumors
The Genopole team SysFate is participating in the international project T-FITNESS. The project, selected by the European Innovation Council, aims to resolve the difficulty of T-cell exhaustion in CAR-T therapies for solid tumors.
13 September 2022
Read the articleToward the genomic selection of farmed insects
France is historically a land of livestock farming. Cows for meat or milk, sheep, pigs, fowl of all sorts; France rears them all. And insects! With its genomic selection project for Tenebrio molitor beetles, the Genopole company Ÿnsect and its biocluster partner, the sequencing center Genoscope, are making France a pioneer in insect farming.
11 July 2022
Read the articleA feat in the study of planktonic life
A Genoscope research team was part of a pioneering study in environmental genomics. The researchers were able to at least partially reconstitute the genomes of close to 700 eukaryote species.
09 June 2022
Read the articleA two-drug combination to treat limb-girdle muscular dystrophies and cystic fibrosis
The I-Stem and Genethon laboratories have identified a promising drug combination in the setting of three genetic diseases sharing similar molecular mechanisms.
17 May 2022
Read the articleAn artificial intelligence to diagnose and explain
The IBISC laboratory has conceived an architecturally-innovative neural network able to provide not only a diagnostic prediction but also a biological explanation.
05 April 2022
Read the articleNews from the human genome
The 1 April edition of Science announced the publication of the human genome with the previously-missing 8% now added to it. Comments from the Genopole Director of Research.
04 April 2022
Read the articleConsequences of phthalate exposure during pregnancy
Jörg Tost and his team of the National Center of Human Genomics Research (CNRGH; CEA) were part of a large collaborative study aimed at determining the genome-wide correlation between phthalate exposure during pregnancy and methylation of placental DNA.
15 March 2022
Read the articleLong-term efficacy for an immunodeficiency gene therapy
A gene therapy conceived by Genethon has been shown to confer long-term efficacy against Wiskott-Aldrich syndrome, an immune deficiency disorder.
18 February 2022
Read the articleA cellular model to recreate the human muscle-nerve system
Researchers from I-Stem, IPSEN and LMN have conceived a cellular muscle-nerve model to test the therapeutic potential of botulinum toxins in vitro.
27 January 2022
Read the articleFilling the gaps in the banana’s genome
Des chercheurs de Genoscope en collaboration avec une équipe du Cirad sont parvenus à reconstituer la séquence intégrale de chromosomes de bananier.
16 December 2021
Read the articleMultiple sclerosis and COVID-19: promising results from AB Science
AB Science has been announcing a series of positive results concerning the efficacy of its product, masitinib, in such pathologies as multiple sclerosis, severe asthma resistant to oral steroids, COVID-19 and amyotrophic lateral sclerosis.
24 September 2020
Read the articleCOFUND-MSCA2020 : ApogeeBio chosen by the EC
Submitted by Genopole and its on-site partners, the ApogeeBio project for research grants has been selected by the European Commission for Marie Skłodowska-Curie Actions co-funding (MSCA-Cofund-2020).
8 February 2021
Read the articleGreen light from Europe for the Genopole-coordinated project GEN.ERA
Le projet européen GEN.ERA*, coordonné par Genopole, est sélectionné par la Commission européenne. Il vise à renforcer par une coopération entre clusters, l’internationalisation d’entreprises du secteur de la génomique au-delà du continent européen.
14 February 2020
Read the articleCRISPR-Cas9 for blood and metabolic diseases – Integrare
In an article published in Nature Communications, an Integrare team headed by Dr. Mario Amendola has described an innovative genome editing strategy aimed at modifying hematopoietic stem cells.
2 September 2020
Read the articleToward the industrialization of gene therapies -Polytheragene
Polytheragene is developing a polymer that will improve upon the current market standards for the production of viral particles for therapeutics. The polymer will be used by Genethon and Yposkesi to enhance the bioproduction of gene therapy vectors.
26 March 2020
Read the article